Imricor Medical Systems Inc
ASX:IMR

Watchlist Manager
Imricor Medical Systems Inc Logo
Imricor Medical Systems Inc
ASX:IMR
Watchlist
Price: 1.995 AUD 3.37% Market Closed
Market Cap: AU$640.3m

Cash Flow Statement

Cash Flow Statement
Imricor Medical Systems Inc

Rotate your device to view
Cash Flow Statement
Currency: USD
Dec-2019 Jun-2020 Dec-2020 Jun-2021 Dec-2021 Jun-2022 Dec-2022 Jun-2023 Dec-2023 Jun-2024 Dec-2024 Jun-2025 Dec-2025
Operating Cash Flow
Net Income
(13)
(14)
(12)
(17)
(20)
(20)
(17)
(17)
(23)
(20)
(30)
(36)
(25)
Depreciation & Amortization
0
0
1
1
1
1
1
1
1
1
1
1
1
Stock-Based Compensation
1
0
1
1
1
1
0
0
1
0
0
0
1
Other Non-Cash Items
7
5
1
1
2
2
1
1
7
5
14
19
5
Cash Interest Paid
0
0
0
0
0
0
0
0
0
0
0
0
0
Change in Working Capital
(1)
(1)
(1)
(1)
(0)
(0)
(1)
1
2
(1)
(1)
(0)
(0)
Cash from Operating Activities
(7)
N/A
(9)
-41%
(12)
-31%
(15)
-26%
(17)
-13%
(17)
+3%
(17)
+3%
(14)
+14%
(13)
+9%
(15)
-14%
(16)
-5%
(17)
-7%
(19)
-14%
Investing Cash Flow
Capital Expenditures
(0)
(1)
(1)
(1)
(1)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
Other Items
(0)
(0)
(0)
0
(0)
0
0
0
0
0
0
0
(21)
Cash from Investing Activities
(1)
N/A
(1)
-76%
(1)
+17%
(1)
+4%
(1)
+7%
(0)
+41%
(0)
+42%
(0)
+17%
(0)
+58%
(0)
+53%
(0)
-93%
(0)
-268%
(22)
-7 767%
Financing Cash Flow
Net Issuance of Common Stock
7
20
33
20
12
12
2
2
6
15
31
65
43
Net Issuance of Debt
3
(0)
(0)
(0)
(1)
(1)
2
5
2
(0)
(1)
(0)
(0)
Other
0
0
0
0
0
0
(0)
(0)
(0)
0
0
0
0
Cash from Financing Activities
10
N/A
20
+92%
33
+65%
20
-39%
12
-42%
11
-5%
4
-64%
7
+73%
8
+21%
15
+80%
30
+105%
64
+112%
43
-33%
Change in Cash
Effect of Foreign Exchange Rates
0
(0)
0
0
(0)
(0)
(0)
(0)
(0)
0
0
1
2
Net Change in Cash
3
N/A
10
+180%
20
+108%
4
-79%
(7)
N/A
(6)
+2%
(13)
-97%
(8)
+41%
(5)
+36%
(0)
+100%
15
N/A
49
+228%
4
-92%
Free Cash Flow
Free Cash Flow
(7)
N/A
(10)
-44%
(13)
-29%
(16)
-25%
(18)
-12%
(17)
+4%
(17)
+4%
(14)
+14%
(13)
+9%
(15)
-14%
(16)
-6%
(17)
-8%
(20)
-15%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett